Developability: polyreactivity and plasma protein binding

Two early checks on the intact antibody, on the same instrument as the target kinetics. Does it bind surfaces it should not? How much plasma protein does it pick up?

The question

Does my candidate bind things it should not, in buffer and in plasma?

Cross-interaction has been associated with faster antibody clearance in mice. Polyreactivity is one of several developability flags, not a reliable predictor on its own. For plasma, the question is whether plasma protein binds to it, and whether it stays bound. Both questions usually need separate platforms. Here, polyreactivity is checked for all candidates, and plasma binding for the ones that pass. See where the panels fit in antibody development.

Polyreactivity

The Polyreactivity Panel carries ligands that each stand for one kind of unwanted interaction: charge, lipid, glycan, plasma protein or nucleic acid. The antibody is titrated over all of them at once.

The setup

Chip8-plex DNA chip; each ligand reaches its molograms by DNA-directed immobilization (DDI)
LigandsPolyreactivity Panel positions 1 to 8: Protein A/G (capture control), dsDNA, human serum albumin (HSA), insulin, human lysozyme, aminocardiolipin, aminoheparin, α1-acid glycoprotein (AGP)
AnalyteSix therapeutic antibodies, one per run: briakinumab, rituximab, ravulizumab, adalimumab, ustekinumab, eculizumab
AssaySingle-cycle titration: a blank, then 111 nM, 333 nM, 1 µM and 3 µM, 120 s each. One antibody per cycle on the same chip, regenerated and loaded again in between
ReadoutResponse at the end of the 3 µM step, blank-corrected, divided by the ligand mass on the same mologram and averaged over eight molograms. The Polyreactivity Index is the mean over the seven panel ligands; its detection limit is 0.03. Retention is the share of signal left 200 s after the injection, on the ligand with the largest response
Load, titrate, wash, fingerprint, plasma

Each position follows a 1:1 model during the titration from the setup table. Play it with the polyreactive antibody, then switch to the clean antibody and play it again. Step 5 shows the plasma protein binding assay.

In the animation, the panel ligands share one koff, set by the measured HSA retention of 0.29 after 200 s. Their KD of 3 µM and the bar heights are not measured. Only the order of the bars follows the measured result. In step 5, bound protein is set to 50 % of the captured antibody, and the toggle does not apply.

Measured result

Two sensorgrams over 27 minutes, briakinumab on top and rituximab below, with five injections from 0 to 3 µM. For both antibodies the Protein A/G trace rises at the first step and stays up. For briakinumab the seven panel ligand traces rise at each step, HSA most, and fall again after each injection. For rituximab the panel ligand traces stay at zero.
Briakinumab (top) and rituximab (bottom) titrated over the Polyreactivity Panel: blank, 111 nM, 333 nM, 1 µM and 3 µM, 120 s each (gray bands). Median change in coherent mass density (CMD) per ligand, divided by that ligand's loading.

How to read it

Plasma protein binding

Plasma protein binding is an assay, not a panel. Each antibody is captured on its own molograms, then undiluted pooled human EDTA plasma or serum flows over the chip. See the capture adapters.

The setup

CaptureAn anti-Fc antibody placed by DDI binds the Fc region of each antibody. All six antibodies on one chip, eight molograms each, with an anti-Fc and a DNA reference
AntibodiesThe same six: rituximab, eculizumab, ustekinumab, ravulizumab, briakinumab, adalimumab
SampleUndiluted pooled human EDTA plasma, and undiluted serum in a separate measurement
ReadoutBound protein mass at the end of the last injection, as a percentage of the captured antibody mass (CMD). No reference subtraction. Eight values per antibody and matrix

Measured result

Two box plots of bound protein as a percentage of captured antibody for six antibodies. Plasma, left: medians from about 25 % for rituximab to about 88 % for ravulizumab, all above a dashed line at 10 %. Serum, right: higher values, from about 68 % for adalimumab to about 423 % for ustekinumab.
Protein bound from plasma (left) and serum (right) to six captured antibodies, read at the end of the injection, as % of captured antibody. Boxes show eight values each. Dashed line: 10 % of captured antibody, drawn as a visual guide, not a validated threshold.

How to read it

Why it works

The MACS Matchmaker reads coherent mass density: only mass that binds in the line pattern of the mologram builds the signal. Proteins that stick evenly to ridges and grooves add no coherent signal, so plasma and serum can flow over the chip. Matched grooves keep this adsorption even, also in crude samples.

Read more: how backfilling matches the grooves, why shared changes cancel, and measuring in serum, plasma and lysate.

More